TYR and melanoma: Because priming of the anti-melanoma immune response during MIC therapy depends upon the interaction of monobenzone with tyrosinase in skin melanocytes, and the induced immune response encompasses more melanosomal antigens besides tyrosinase (figure 4B and manuscript in preparation), our MIC regimen may well be effective against tyrosinase-negative melanoma variants.